Clinical Scorecard: Long-Term Outcomes of Sleeve Gastrectomy Compared to Roux-en-Y Gastric Bypass: A Systematic Review and Meta-Analysis Over a Decade
At a Glance
Category
Detail
Condition
Severe obesity and related comorbidities
Key Mechanisms
Bariatric surgery procedures: Sleeve Gastrectomy (SG) and Roux-en-Y Gastric Bypass (RYGB) for weight loss and metabolic control
Target Population
Patients with morbid obesity undergoing bariatric surgery
Care Setting
Surgical and postoperative follow-up care in bariatric/metabolic surgery centers
Key Highlights
No statistically significant difference in total weight loss (%TWL) and excess weight loss (%EWL) between SG and RYGB at 10-year follow-up.
RYGB shows a slight, non-significant advantage in weight loss maintenance over SG in long-term outcomes.
Long-term remission rates of diabetes mellitus and other comorbidities show no significant difference between SG and RYGB.
Guideline-Based Recommendations
Diagnosis
Evaluate patients with morbid obesity for eligibility for bariatric surgery including SG and RYGB.
Assess baseline comorbidities such as diabetes mellitus, hypertension, and dyslipidemia prior to surgery.
Management
Consider both SG and RYGB as effective long-term surgical options for weight loss and metabolic disease remission.
Individualize surgical choice based on patient-specific factors, comorbidities, and risk profiles.
Provide multidisciplinary postoperative care and lifestyle support to optimize long-term outcomes.
Monitoring & Follow-up
Conduct long-term follow-up (≥10 years) to monitor weight loss maintenance and comorbidity remission.
Regularly assess metabolic parameters including glycemic control, lipid profiles, and blood pressure.
Monitor for potential complications and nutritional deficiencies associated with each procedure.
Risks
Recognize that both procedures carry risks inherent to bariatric surgery; no significant difference in long-term adverse outcomes reported.
Consider procedure-specific risks such as gastroesophageal reflux disease (GERD) more commonly associated with SG.
Patient & Prescribing Data
Morbidly obese adults undergoing bariatric surgery with at least 10 years of follow-up data.
Both SG and RYGB provide durable weight loss and comorbidity remission over a decade, with no statistically significant superiority of one procedure over the other in long-term outcomes.
Clinical Best Practices
Use shared decision-making incorporating patient preferences, comorbidity profiles, and surgical risk when selecting SG versus RYGB.
Ensure comprehensive preoperative evaluation and counseling regarding expected long-term outcomes and potential risks.
Implement structured long-term follow-up protocols to monitor weight, metabolic health, and nutritional status.
Maintain awareness of moderate heterogeneity in study outcomes and interpret meta-analysis results within clinical context.
